A retrospective cohort study to determine comparative effectiveness of BNT162b2 and mRNA-1273 among patients with SARDs against COVID-19 infection
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 15 Jan 2023 Results (n=9838 ) comparing the effectiveness of BNT162b2 vs mRNA-1273 against COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) on immunomodulatory medications, published in The Journal of Rheumatology
- 30 Dec 2022 New trial record
- 14 Nov 2022 Results presented at the ACR Convergence 2022